Company Description
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum.
The company also offers delivery models that include full service, functional service provider, and hybrid service structures.
In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services.
Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines.
Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16,120 |
| CEO | Peter Neupert |
Contact Details
Address: 8 Moore Drive Durham, North Carolina 27709 United States | |
| Phone | 877 495 0816 |
| Website | fortrea.com |
Stock Details
| Ticker Symbol | FTRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001965040 |
| CUSIP Number | 34965K107 |
| ISIN Number | US34965K1079 |
| Employer ID | 92-2796441 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Peter M. Neupert | Interim Chief Executive Officer, Chairman of the Board and Lead Independent Director |
| Jill McConnell | Chief Financial Officer |
| Mark A. Morais | Chief Operating Officer and President of Clinical Services |
| Drayton Virkler | President and Chief Commercial Officer |
| Robert Parks | Chief Accounting Officer |
| Alejandro Martinez Galindo | Chief Information Officer |
| Dave Cooper | Chief Administrative Officer |
| Hima B. Inguva | Head of Investor Relations and Corporate Development |
| J. Stillman Hanson J.D. | General Counsel and Corporate Secretary |
| Dr. Oren J. Cohen M.D. | Chief Medical Officer and President of Clinical Pharmacology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-A12B | Registration of securities |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 144 | Filing |
| Jun 3, 2025 | 144 | Filing |
| Jun 3, 2025 | 144 | Filing |
| May 15, 2025 | 8-K/A | [Amend] Current report |
| May 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 15, 2025 | SCHEDULE 13G/A | Filing |